BALTIMORE--(BUSINESS WIRE)--CSA Medical, Inc., the leading provider of advanced spray cryotherapy technology that flash freezes unhealthy tissue inside the body, today announced that clinicians at the University of Colorado Hospital have completed the 10,000th spray cryotherapy procedure. The company’s latest technology platform, the truFreeze System, was used during the procedure and will also be featured this week in the CSA Medical exhibit at the Digestive Disease Week (DDW) 2013 Annual Meeting in Orlando, FL.
Norio Fukami, MD, associate professor of medicine at the University of Colorado School of Medicine and interventional endoscopist in the Gastroenterology and Hepatology Division at the University of Colorado Hospital, used the truFreeze device during the 10,000th procedure. “The truFreeze Spray Cryotherapy System is a powerful complement to other treatment modalities and an important new option for patients suffering from esophageal disease and more. We have found that liquid nitrogen spray enables us to access bumpy or scarred diseased tissue surfaces that are often difficult to treat with contact based ablation methods and that depth of treatment can be modified as needed," said Fukami. "Spray cryotherapy is also well-tolerated by patients and has the most favorable patient recovery profile of various endoscopic resection or ablation techniques we’ve used.”
Spray cryotherapy is usually an outpatient procedure during which a physician inserts an endoscope through the mouth to enable viewing of the esophagus. The physician then inserts a specialized catheter through the endoscope, selects the targeted area and sprays liquid nitrogen to flash freeze the tissue. After the selected tissue is frozen for a short period of time, the area is allowed to thaw naturally and the freeze-thaw cycle is repeated as determined necessary by the physician. This process has been shown to destroy the sprayed cells without disturbing the underlying connective tissue, thereby providing a framework for healthy cells to regenerate over time.
CSA Medical’s spray cryotherapy technology was first introduced to the market in 2007 for the ablation of unwanted tissue during endoscopic procedures. “This 10,000th procedure milestone reflects the growing clinical interest in and acceptance of spray cryotherapy,” said Bill Floyd, CEO and President of CSA Medical. “This is a clinical intervention that is here to stay and we are committed to continuing to work with the medical community to further advance our technology and help clinicians bring the benefits of spray cryotherapy to more patients.”
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform comprised of a device and specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unhealthy tissue. The Company is the first to harness the power of low pressure, extremely cold (-196 o C) liquid nitrogen inside the body. To learn more, please visit www.CSAmedical.com.